Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M

Castle's current portfolio consists of tests for skin cancers, uveal melanoma and Barrett ’s esophagus, the firm said.

Source: bizjournals.com Health Care:Physician Practices headlines - April 5, 2022 Category: American Health Authors: Chris Mathews Source Type: news